ReviewTransplantation2013
Costimulation blockade: current perspectives and implications for therapy.
Review in Transplantation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 81 citations in OpenAlex.
- Advanced immunotherapy across diseases and the role of artificial intelligence: A review.Biomolecules & biomedicine · 2026Review
- Surveillance and prevention of infection in clinical xenotransplantation.Clinical microbiology reviews · 2025Review
- Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- Immunoprotection of cellular transplants for autoimmune type 1 diabetes through local drug delivery.Advanced drug delivery reviews · 2024Review
- TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate cardiac allograft survival.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2023Article
- Transcriptomic analysis of graft liver provides insight into the immune response of rat liver transplantation.Frontiers in immunology · 2022Article
- Recent Advances in Costimulatory Blockade to Induce Immune Tolerance in Liver Transplantation.Frontiers in immunology · 2021Review
- Article
- The immune system in infants: Relevance to xenotransplantation.Pediatric transplantation · 2020Review
- The impact of belatacept on the phenotypic heterogeneity of renal T cell-mediated alloimmune response: The critical role of maintenance treatment and inflammatory load.Clinical transplantation · 2020Article
- Capacity of Retinal Ganglion Cells Derived from Human Induced Pluripotent Stem Cells to Suppress T-Cells.International journal of molecular sciences · 2020Article
- Vascularized composite allotransplantation combined with costimulation blockade induces mixed chimerism and reveals intrinsic tolerogenic potential.JCI insight · 2020Article
- Costimulation Blockade in Vascularized Composite Allotransplantation.Frontiers in immunology · 2020Review
- Induction of immunological tolerance to myelinogenic glial-restricted progenitor allografts.Brain : a journal of neurology · 2019Article
- Interruption of OX40L signaling prevents costimulation blockade-resistant allograft rejection.JCI insight · 2017Article
- Immunomodulatory effects of OX40Ig gene-modified adipose tissue-derived mesenchymal stem cells on rat kidney transplantation.International journal of molecular medicine · 2017Article
- BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.Frontiers in immunology · 2017Review
- Review
- Prevention of allograft rejection in heart transplantation through concurrent gene silencing of TLR and Kinase signaling pathways.Scientific reports · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
T cells must be activated before they can elicit damage to allografts, through interaction of their T cell receptor (TCR) with peptide-MHC complex and through accessory molecules. Signaling through accessory molecules or costimulatory molecules is a critical way for the immune system to fine tune T cell activation. An emerging therapeutic strategy is to target selective molecules involved in the process of T cell activation using biologic agents, which do not impact TCR signaling, thus only manipulating the T cells, which recognize alloantigen. Costimulatory receptors and their ligands are attractive targets for this strategy and could be used both to prevent acute graft rejection as well as for maintenance immunosuppression. Therapeutic agents targeting costimulatory molecules, notably belatacept, have made the progression from the bench, through nonhuman primate studies and into the clinic. This overview describes some of the most common costimulatory molecules, their role in T cell activation, and the development of reagents, which target these pathways and their efficacy in transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.